High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1–infected patients with severe chronic kidney disease

Background & Aims Limited data have shown high efficacy of co‐formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)‐4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stages 4‐5 (

Saved in:
Bibliographic Details
Published in:Liver international 2018-08, Vol.38 (8), p.1395-1401
Main Authors: Sanai, Faisal M., Alghamdi, Abdullah S., Afghani, Ahmad A., Alswat, Khalid, AlZanbagi, Adnan, Alghamdi, Mosfer N., AlMousa, Abdallah, Aseeri, Mohammed, Assiri, Abdullah M., Babatin, Mohamed A.
Format: Article
Language:English
Subjects:
Adult
Anemia
Anilides - therapeutic use
Antiviral Agents - therapeutic use
Carbamates - therapeutic use
chronic kidney disease
Cirrhosis
Cohort Studies
Complications
Disease control
Drug Therapy, Combination
Effectiveness
Female
Females
genotype 4
Genotypes
Hemodialysis
Hepacivirus - genetics
Hepatitis
Hepatitis C
hepatitis C virus
Hepatitis C, Chronic - complications
Hepatitis C, Chronic - drug therapy
Humans
Kidney diseases
Kidneys
Liver cirrhosis
Liver Cirrhosis - virology
Macrocyclic Compounds - therapeutic use
Male
Middle Aged
Motivation
Myocardial infarction
ombitasvir
paritaprevir
Patients
Registries
Renal Insufficiency, Chronic - complications
Ribavirin - therapeutic use
Ritonavir
Ritonavir - therapeutic use
Safety
Saudi Arabia
Sepsis
Sulfonamides - therapeutic use
Sustained Virologic Response
Uracil - analogs & derivatives
Uracil - therapeutic use
Viruses
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background & Aims Limited data have shown high efficacy of co‐formulated ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in the treatment of hepatitis C virus (HCV) genotype (GT)‐4, and combined with dasabuvir (DSV) in GT1 patients, with chronic kidney disease (CKD) stages 4‐5 (
ISSN:1478-3223
1478-3231
DOI:10.1111/liv.13674